NextCure (NASDAQ:NXTC) Major Shareholder Acquires $18,120.30 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 3,553 shares of the firm’s stock in a transaction on Tuesday, October 27th. The stock was acquired at an average price of $5.10 per share, for a total transaction of $18,120.30. Following the completion of the transaction, the insider directly owned 733,270 shares of the company’s stock, valued at approximately $3,739,677. This trade represents a 0.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The shares were acquired at an average price of $5.03 per share, for a total transaction of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc acquired 5,626 shares of NextCure stock. The shares were acquired at an average cost of $4.83 per share, with a total value of $27,173.58.
• On Friday, July 31st, Adar1 Capital Management, Llc acquired 36,303 shares of NextCure stock. The shares were acquired at an average cost of $4.94 per share, with a total value of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc acquired 292,850 shares of NextCure stock. The stock was bought at an average price of $4.93 per share, with a total value of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, for a total transaction of $17,050.00.

NextCure Price Performance

NextCure stock traded up $0.50 during trading on Tuesday, reaching $5.72. The company had a trading volume of 142,082 shares. The firm’s 50-day simple moving average is $6.11 and its 200 day simple moving average is $7.99. NextCure, Inc. has a 52 week low of $1.55 and a 52 week high of $15.74.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NXTC. Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. HC Wainwright reissued a “buy” rating on shares of NextCure in a report on Thursday, August 13th. Finally, Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $19.00.

Institutional Inflows and Outflows

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC increased its position in NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 60,534 shares of the company’s stock after buying an additional 26,900 shares during the period. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 at the end of the most recent quarter. 42.65% of the stock is currently owned by institutional investors.

About NextCure

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.